Microbion Corporation

Microbion Corporation is a clinical-stage pharmaceutical company based in Bozeman, MT, dedicated to developing a new class of compounds for the treatment of challenging infections, including antibiotic-resistant and chronic infections. Their lead therapeutic candidate, Pravibismane, is a groundbreaking anti-infective drug with broad-spectrum activity that effectively prevents and eradicates biofilms, which contribute to chronic infections and antibiotic resistance.

With a focus on site-specific delivery, Microbion's innovative approach avoids systemic administration of their compounds, allowing for higher therapeutic concentrations at the site of infection, resulting in improved efficacy, safety, and reduced risk of antibiotic resistance. They have ongoing Phase 2 clinical programs for the treatment of diabetic foot ulcer infection and orthopedic device-related infection, as well as pre-clinical programs for the treatment of respiratory infections. Microbion is committed to developing breakthrough options that address unmet medical needs and improve the lives of patients.

Generated from the website